Compare Stocks: VCYT, TWST, BMRN, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$65.51 +1.7%	$63.16	$49.26 ▼ $70.98	$12.47B	0.24	1.72 million shs	2.20 million shs
HALO Halozyme Therapeutics	$107.00 -0.4%	$93.18	$61.22 ▼ $111.15	$12.19B	0.88	1.59 million shs	1.46 million shs
TWST Twist Bioscience	$126.85 +1.1%	$112.95	$23.30 ▼ $155.44	$7.87B	2.22	1.52 million shs	1.28 million shs
VCYT Veracyte	$42.03 -4.2%	$49.34	$29.45 ▼ $60.91	$3.53B	1.93	1.25 million shs	849,420 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+1.71%	-1.38%	-5.81%	+17.09%	+20.20%
HALO Halozyme Therapeutics	-0.36%	-3.39%	+4.27%	+53.96%	+41.16%
TWST Twist Bioscience	+1.06%	-1.45%	+3.03%	+66.54%	+425.04%
VCYT Veracyte	-4.17%	-5.91%	-9.44%	-11.20%	+36.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$65.51 +1.7%	$63.16	$49.26 ▼ $70.98	$12.47B	0.24	1.72 million shs	2.20 million shs
HALO Halozyme Therapeutics	$107.00 -0.4%	$93.18	$61.22 ▼ $111.15	$12.19B	0.88	1.59 million shs	1.46 million shs
TWST Twist Bioscience	$126.85 +1.1%	$112.95	$23.30 ▼ $155.44	$7.87B	2.22	1.52 million shs	1.28 million shs
VCYT Veracyte	$42.03 -4.2%	$49.34	$29.45 ▼ $60.91	$3.53B	1.93	1.25 million shs	849,420 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+1.71%	-1.38%	-5.81%	+17.09%	+20.20%
HALO Halozyme Therapeutics	-0.36%	-3.39%	+4.27%	+53.96%	+41.16%
TWST Twist Bioscience	+1.06%	-1.45%	+3.03%	+66.54%	+425.04%
VCYT Veracyte	-4.17%	-5.91%	-9.44%	-11.20%	+36.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	36.12% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-14.77% Downside
TWST Twist Bioscience	2.50	Moderate Buy	$98.45	-22.39% Downside
VCYT Veracyte	2.82	Moderate Buy	$55.78	32.71% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$60.00
9/9/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/9/2026	VCYT Veracyte	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $65.00
9/9/2026	TWST Twist Bioscience	BWS Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$45.00
9/9/2026	TWST Twist Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$144.00
9/3/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.94	$2.90 per share	22.58	$31.68 per share	2.07
HALO Halozyme Therapeutics	$1.40B	8.70	$4.75 per share	22.51	$0.42 per share	254.76
TWST Twist Bioscience	$376.57M	21.12	N/A	N/A	$7.84 per share	16.18
VCYT Veracyte	$517.15M	6.53	$1.43 per share	29.45	$16.57 per share	2.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	177.05	12.02	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	31.94	11.56	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	11/13/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	29.81	27.29	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest VCYT, TWST, BMRN, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
HALO Halozyme Therapeutics	13.50	2.71	2.31
TWST Twist Bioscience	0.03	2.67	2.38
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
HALO Halozyme Therapeutics	97.79%
TWST Twist Bioscience	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
HALO Halozyme Therapeutics	2.50%
TWST Twist Bioscience	3.08%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
TWST Twist Bioscience	979	62.71 million	60.78 million	Optionable
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

VCYT, TWST, BMRN, and HALO Headlines

Recent News About These Companies

Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors

September 9 at 9:00 PM | gurufocus.com

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

September 9 at 10:06 AM | zacks.com

Insider Selling: Veracyte (NASDAQ:VCYT) Insider Sells $564,385.50 in Stock

September 7, 2026 | americanbankingnews.com

Veracyte (NASDAQ:VCYT) Stock Price Down 4.5% After Insider Selling

September 6, 2026 | americanbankingnews.com

Insider Selling: Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares

September 5, 2026 | insidertrades.com

Veracyte (NASDAQ:VCYT) EVP Sells 3,254 Shares of Stock

September 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) CFO Sells 3,652 Shares

September 4, 2026 | marketbeat.com

Phillip Febbo Sells 13,110 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Shares Down 4.5% After Insider Selling

September 4, 2026 | marketbeat.com

Muna Bhanji Sells 1,864 Shares of Veracyte (NASDAQ:VCYT) Stock

September 4, 2026 | insidertrades.com

Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells 1,864 Shares of Stock

September 3, 2026 | marketbeat.com

22,291 Shares in Veracyte, Inc. $VCYT Acquired by Man Group plc

September 3, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Purchases New Stake in Veracyte, Inc. $VCYT

September 3, 2026 | marketbeat.com

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026 | globenewswire.com

Veracyte, Inc. $VCYT Shares Sold by Moore Capital Management LP

September 1, 2026 | marketbeat.com

Wellington Management Group LLP Lowers Position in Veracyte, Inc. $VCYT

September 1, 2026 | marketbeat.com

161,973 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LP

August 31, 2026 | marketbeat.com

Alyeska Investment Group L.P. Lowers Stock Position in Veracyte, Inc. $VCYT

August 31, 2026 | marketbeat.com

269,806 Shares in Veracyte, Inc. $VCYT Purchased by Jupiter Topco LLC

August 30, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT

August 30, 2026 | marketbeat.com

437,604 Shares in Veracyte, Inc. $VCYT Purchased by Bank of New York Mellon Corp

August 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$65.51 +1.10 (+1.71%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$66.14 +0.63 (+0.96%)

As of 07:00 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Halozyme Therapeutics NASDAQ:HALO

$107.00 -0.39 (-0.36%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$107.92 +0.92 (+0.86%)

As of 07:01 AM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Twist Bioscience NASDAQ:TWST

$126.85 +1.33 (+1.06%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$125.40 -1.45 (-1.14%)

As of 06:59 AM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte NASDAQ:VCYT

$42.03 -1.83 (-4.17%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$42.42 +0.39 (+0.94%)

As of 07:05 AM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Halozyme Therapeutics NASDAQ:HALO

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, BMRN, and HALO Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Halozyme Therapeutics NASDAQ:HALO

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools